Sales of migraine drug exceed expectations at Lundbeck during third quarter

The third quarter financial results at Lundbeck were more or less as expected, though one high point was miraine drug Vyepti, where sales surpassed analysts' expectations. The company is turning up the heat on the US market as it looks to the future.

Photo: Thomas Borberg

There were no surprises in Lundbeck's Q3 report released on Wednesday morning. The company has more or less performed as it expected to – exceeding some targets, meeting some exactly, and narrowly missing others.

Revenue is one of the parameters where the company came in slightly under analysts' estimates. As expected, the company has suffered from patent loss for its drug Northera, but this has had a greater impact than expected, with revenue totaling DKK 4013 (USD 624.4m) compared to the predicted DKK 4074m (USD 633.9m).

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs